ChemicalBook > CAS DataBase List > Ralpancizumab
Ralpancizumab
- Product Name
- Ralpancizumab
- CAS No.
- 1407495-04-8
- Chemical Name
- Ralpancizumab
- Synonyms
- Ralpancizumab;Ralpancizumab (anti-PCSK9);Research Grade Ralpancizumab;Research Grade Ralpancizumab (DHJ24006)
- CBNumber
- CB38080898
- Formula Weight
- 0
- MOL File
- Mol file
More
Less
Ralpancizumab Chemical Properties,Usage,Production
Uses
Ralpancizumab is a selective PCSK9 inhibitor with potential application in hemorrhagic stroke[1].
References
[1] Sanz-Cuesta BE, et al. Lipid-Lowering Therapy and Hemorrhagic Stroke Risk: Comparative Meta-Analysis of Statins and PCSK9 Inhibitors. Stroke. 2021 Oct;52(10):3142-3150. DOI:10.1161/STROKEAHA.121.034576
Ralpancizumab Preparation Products And Raw materials
Raw materials
Preparation Products
More
Less
Ralpancizumab Suppliers
- Tel
- 021-61312847; 18021002903
- Fax
- QQ:3008007432
- 3008007409@qq.com
- Country
- China
- ProdList
- 71826
- Advantage
- 60
- Tel
- 177-54423994 17754423994
- Fax
- QQ:2853530913
- 2853530910@QQ.com
- Country
- China
- ProdList
- 8000
- Advantage
- 62
- Tel
- 15817493340
- 981810490@qq.com
- Country
- China
- ProdList
- 1566
- Advantage
- 58
- Tel
- 027-65317797 15926423062
- Fax
- QQ:422450190
- 422450190@qq.com
- Country
- China
- ProdList
- 10308
- Advantage
- 58
- Tel
- 027-65279366 18108604356
- products@biolabreagent.com
- Country
- China
- ProdList
- 9868
- Advantage
- 58
- Tel
- 13720134139 086-15871494362 13720134139
- orders@jknbiochem.com
- Country
- China
- ProdList
- 6762
- Advantage
- 58
- Tel
- 021-65675885 18964387627
- customer_service@efebio.com
- Country
- China
- ProdList
- 11973
- Advantage
- 58
- Tel
- 0731-13823398 15111215862
- 313359644@qq.com
- Country
- China
- ProdList
- 4161
- Advantage
- 58
- Tel
- 17316404525 17316404525
- 209533805@qq.com
- Country
- China
- ProdList
- 9763
- Advantage
- 58
- Tel
- 0573-83568680 18057391398
- 3956524501@qq.com
- Country
- China
- ProdList
- 1442
- Advantage
- 58
1407495-04-8, RalpancizumabRelated Search:
Begelomab
Anumigilimab
Suvratoxumab
Lacutamab
Sirtratumab
Research Grade Clivatuzumab (DHD14205)
Tuvonralimab
Ianalumab
Romilkimab
Mavezelimab